159 related articles for article (PubMed ID: 12634619)
1. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
Swenson CE; Bolcsak LE; Batist G; Guthrie TH; Tkaczuk KH; Boxenbaum H; Welles L; Chow SC; Bhamra R; Chaikin P
Anticancer Drugs; 2003 Mar; 14(3):239-46. PubMed ID: 12634619
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
4. Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients.
Embree L; Gelmon KA; Lohr A; Mayer LD; Coldman AJ; Cullis PR; Palaitis W; Pilkiewicz F; Hudon NJ; Heggie JR
J Pharm Sci; 1993 Jun; 82(6):627-34. PubMed ID: 8392545
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.
Shapiro CL; Ervin T; Welles L; Azarnia N; Keating J; Hayes DF
J Clin Oncol; 1999 May; 17(5):1435-41. PubMed ID: 10334528
[TBL] [Abstract][Full Text] [Related]
6. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.
Harris L; Batist G; Belt R; Rovira D; Navari R; Azarnia N; Welles L; Winer E;
Cancer; 2002 Jan; 94(1):25-36. PubMed ID: 11815957
[TBL] [Abstract][Full Text] [Related]
7. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer.
Rushing DA; Raber SR; Rodvold KA; Piscitelli SC; Plank GS; Tewksbury DA
Cancer; 1994 Aug; 74(3):834-41. PubMed ID: 8039111
[TBL] [Abstract][Full Text] [Related]
8. Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).
Linkesch W; Weger M; Eder I; Auner HW; Pernegg C; Kraule C; Czejka MJ
Eur J Drug Metab Pharmacokinet; 2001; 26(3):179-84. PubMed ID: 11695718
[TBL] [Abstract][Full Text] [Related]
9. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
Batist G; Ramakrishnan G; Rao CS; Chandrasekharan A; Gutheil J; Guthrie T; Shah P; Khojasteh A; Nair MK; Hoelzer K; Tkaczuk K; Park YC; Lee LW
J Clin Oncol; 2001 Mar; 19(5):1444-54. PubMed ID: 11230490
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.
Twelves CJ; Dobbs NA; Aldhous M; Harper PG; Rubens RD; Richards MA
Cancer Chemother Pharmacol; 1991; 28(4):302-7. PubMed ID: 1879047
[TBL] [Abstract][Full Text] [Related]
11. Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.
Brenner DE; Galloway S; Cooper J; Noone R; Hande KR
Cancer Chemother Pharmacol; 1985; 14(2):139-45. PubMed ID: 3971478
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
Valero V; Buzdar AU; Theriault RL; Azarnia N; Fonseca GA; Willey J; Ewer M; Walters RS; Mackay B; Podoloff D; Booser D; Lee LW; Hortobagyi GN
J Clin Oncol; 1999 May; 17(5):1425-34. PubMed ID: 10334527
[TBL] [Abstract][Full Text] [Related]
13. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer.
Moreira A; Lobato R; Morais J; Silva S; Ribeiro J; Figueira A; Vale D; Sousa C; Araújo F; Fernandes A; Oliveira J; Passos-Coelho JL
Cancer Chemother Pharmacol; 2001 Oct; 48(4):333-7. PubMed ID: 11710635
[TBL] [Abstract][Full Text] [Related]
14. Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study.
Giotta F; Lorusso V; Maiello E; Filippelli G; Valerio MR; Caruso M; Verderame F; Latorre A; Colucci G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi66-9. PubMed ID: 17591836
[TBL] [Abstract][Full Text] [Related]
15. Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy:a multicenter phase III study.
Lorusso V; Giotta F; Bordonaro R; Maiello E; Del Prete S; Gebbia V; Filippelli G; Pisconti S; Cinieri S; Romito S; Riccardi F; Forcignanò R; Ciccarese M; Petrucelli L; Saracino V; Lupo LI; Gambino A; Leo S; Colucci G;
Int J Oncol; 2014 Nov; 45(5):2137-42. PubMed ID: 25176223
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
17. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit.
Cusack BJ; Tesnohlidek DA; Loseke VL; Vestal RE; Brenner DE; Olson RD
Cancer Chemother Pharmacol; 1988; 22(4):294-8. PubMed ID: 3168142
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer.
Bronchud MH; Margison JM; Howell A; Lind M; Lucas SB; Wilkinson PM
Cancer Chemother Pharmacol; 1990; 25(6):435-9. PubMed ID: 2311172
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker.
Sridhar KS; Krishan A; Samy TS; Duncan RC; Sauerteig A; McPhee GV; Auguste ME; Benedetto PW
Cancer Chemother Pharmacol; 1994; 34(5):377-84. PubMed ID: 8070004
[TBL] [Abstract][Full Text] [Related]
20. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
